MedTrace Logo

Long Term Safety and Efficacy Study of ProSavin in Parkinson's Disease

NCT01856439 · Status: TERMINATED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2022-05-03

No results posted yet for this study

Summary

The study is designed to assess the long term tolerability of ProSavin and whether it is safe and efficacious in patients administered ProSavin from the PS1/001/07 study .

Conditions

Interventions

DRUG

ProSavin

Long term follow up of patients who received ProSavin in a previous study

Sponsors & Collaborators

  • Oxford BioMedica

    collaborator INDUSTRY

  • Axovant Sciences Ltd.

    lead INDUSTRY

Principal Investigators

  • Stephane Palfi, Professor · Henri Mondor University Hospital

  • Roger Barker, Dr · Cambridge University Hospitals NHS Foundation Trust

Study Design

Allocation
NA
Purpose
OTHER
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-05-31
Primary Completion
2021-11-30
Completion
2022-04-30

Countries

  • France
  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01856439 on ClinicalTrials.gov